Vistin Pharma ASA (LTS:0RAM) Retained Earnings: kr232.1 Mil (As of Mar. 2026)


LTS:0RAM Vistin Pharma ASA LTS:0RAM
77 GF Score
Price kr20.70
GF Value kr25.61
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Vistin Pharma ASA Retained Earnings?

Vistin Pharma ASA LTS:0RAM 77 Retained Earnings is kr232.1 Mil as of Mar. 2026. GuruFocus rates LTS:0RAM with a GF Score™ of 77/100 and a GF Value™ of kr25.61 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Vistin Pharma ASA's retained earnings for the quarter that ended in Mar. 2026 was kr232.1 Mil.

Vistin Pharma ASA's quarterly retained earnings increased from Sep. 2025 (kr194.6 Mil) to Dec. 2025 (kr210.6 Mil) and increased from Dec. 2025 (kr210.6 Mil) to Mar. 2026 (kr232.1 Mil).

Vistin Pharma ASA's annual retained earnings increased from Dec. 2023 (kr71.5 Mil) to Dec. 2024 (kr135.9 Mil) and increased from Dec. 2024 (kr135.9 Mil) to Dec. 2025 (kr210.6 Mil).


Vistin Pharma ASA  (LTS:0RAM) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Vistin Pharma ASA Retained Earnings Historical Data

* Premium members only.

The historical data trend for Vistin Pharma ASA's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistin Pharma ASA Retained Earnings Chart

Vistin Pharma ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.54 22.26 71.54 135.89 210.60

Vistin Pharma ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 157.58 176.06 194.58 210.60 232.09
LTS:0RAM
77GF Score
Vistin Pharma ASA LTS:0RAM
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistin Pharma ASA Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of kr232.1 Mil mean?
Vistin Pharma ASA (LTS:0RAM) has a Retained Earnings of kr232.1 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Vistin Pharma ASA and its competitors.
Is Vistin Pharma ASA's Retained Earnings too high?
Vistin Pharma ASA's current Retained Earnings is kr232.1 Mil. Overall, Vistin Pharma ASA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Retained Earnings compare to ZTS and UTHR?
Vistin Pharma ASA's Retained Earnings of kr232.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Vistin Pharma ASA and its competitors. Vistin Pharma ASA's current Retained Earnings is kr232.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.61, compared to a current price of kr20.70 — trading 19.2% below its estimated fair value. The current Retained Earnings is kr232.1 Mil. Vistin Pharma ASA's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Retained Earnings is kr232.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?

Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued. The current stock price of kr20.70 is trading 19.2% below its estimated GF Value™ of kr25.61. GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.

Key valuation signals for LTS:0RAM:

  • Retained Earnings: kr232.1 Mil
  • GF Value™: kr25.61 vs. price of kr20.70 (19.2% below fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vistin Pharma ASA Business Description

Address Ostensjoveien 27, P.O. Box 6735 Etterstad, Oslo, NOR, 0661
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
77GF Score

Get the complete analysis for LTS:0RAM

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr20.70
Price
kr25.61
GF Value